GCG and obesity due to melanocortin 4 receptor deficiency: The positive metabolic effects of OXM, characterized by increased insulin secretion and reduced glycaemic excursion, appeared comparable to liraglutide in individuals with obesity and type 2 diabetes (Pocai et al., 2009).